For one more successive year, IASIS PHARMA participated as a Main Sponsor in the 22nd Greek Conference for Helicobacter pylori and Other Infections of the Digestive Tract. The conference was organized by the Greek Society for the Study of H. pylori (E.E.M.E.P.), took place at Athens Medical School’s Physiology Amphitheater, in Goudi, Athens, from March 31st to April 1st.

IASIS PHARMA organized a Satellite Lecture under the title “Chios Mastic: from research to a unique herbal medicine”, with Dr. Leandros Skaltsounis, Professor of Pharmacognosy and Chemistry of Nartural Products, Faculty of Pharmacy of theNational and Κapodistrian University of Athens, as one of the main speakers.

It was followed by a lecture from Dr. Stavros Sougioultzis,Gastroenterologist, Assistant Professor of Pathophysiology t, under the title: “Chios Mastic & H. pylori: Preliminary Clinical Data”. During his speech, Dr.Sougioultzis introduced the latest findings of a double-blind, placebo controlled, phase IV clinical trial, on the action of Chios Mastic (mastihatherapy® caps) caps of 350mg for the eradication of H. pylori. The results were positive and encouraging for the use of mastihatherapy® caps 350mg as an add on therapy to an antibiotic treatment for the eradication of H. pylori.

It is also worthy to mention the speech of Dr. Christos Zavos, Gastroenterologist – hepatologist, during a Round Table Discussion, under the title: “Control Infections in the general population. Target Groups”, in which he referred to the results of the Dabos KJ., et al Study, (Phytomedicine 2010, 17:296-299) on the posible use, of high dosage Chios Mastic as monotherapy in the general population of young age, who suffer from an asymptomatic Hp infection.


dsc02023-upload  dsc02061-upload